3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Gastrointestinal
1
Conditions
Venous Thrombosis
2
Venous Thromboembolism
2
Pulmonary Embolism
2
Gastrointestinal Neoplasms
1
Interventions
apixaban
22
Rivaroxaban
16
Dalteparin
16
Enoxaparin
11
Heparin, Low-Molecular-Weight
10
Tinzaparin
8
Aspirin
8
Fondaparinux
4
Dabigatran
4
edoxaban
3
Warfarin
3
Nadroparin
3
bemiparin
2
abelacimab
2
Rosuvastatin Calcium
2
Observation
2
MAA868
2
sotorasib
1
ribociclib
1
reviparin
1
palbociclib
1
isoquercitrin
1
enoxaparin sodium
1
certoparin
1
calcium heparin
1
betrixaban
1
argatroban
1
acarboxyprothrombin
1
abemaciclib
1
Tacrolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Venous Thromboembolism
×
abelacimab
×
Classical hematology
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT05171049
2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3
Terminated
1,150 enrolled